Finance

Lists
600998:SHA
Jointown Pharmaceutical Group Co Ltd
CNÂ¥4,93
-1,79%
(-0,090) 1D
16 Okt., 15:00:01 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600998...
Open
CNÂ¥5,02
High
CNÂ¥5,08
Low
CNÂ¥4,88
Mkt. cap
25,36 mjd
Avg. vol.
33,74 m
Volume
44,94 m
Dividend
4,06%
Quarterly dividend
CNÂ¥0,05
Ex-dividend date
08 Jun. 2026
P/E ratio
12,56
52-wk high
CNÂ¥5,84
52-wk low
CNÂ¥4,48
EPS
CNÂ¥0,39
Shares outstanding
1,88 mjd
No. of employees
30 k
Open
CNÂ¥5,02
High
CNÂ¥5,08
Low
CNÂ¥4,88
Mkt. cap
25,36 mjd
Avg. vol.
33,74 m
Volume
44,94 m
Dividend
4,06%
Quarterly dividend
CNÂ¥0,05
Ex-dividend date
08 Jun. 2026
P/E ratio
12,56
52-wk high
CNÂ¥5,84
52-wk low
CNÂ¥4,48
EPS
CNÂ¥0,39
Shares outstanding
1,88 mjd
No. of employees
30 k
News stories
From web sources and news partners
Profile
Jointown Pharmaceutical Group Co., Ltd. is a publicly traded multinational healthcare services company. By revenue, it is the largest medical company in China that is not state-owned. It is also the 4th largest overall. Its global headquarters are in Wuhan, China and its international headquarters are in Los Angeles, California. The company specializes in the distribution of pharmaceuticals and medical products, distributing more than 510,000 products. The company also manufactures products, including gloves, surgical masks, medical equipment and medications. In addition, it operates the largest network of medical warehouses in China. It is one of the largest in the world, at over 44 million square feet. The company has over 400 subsidiaries and provides medical products to all 31 provinces in mainland China. Wikipedia
About Jointown Pharmaceutical Group Co Ltd
CEO-
Employees29,9 k
Founded2000
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
38,22 mjd
42,06 mjd
44,78 mjd
42,50 mjd
Cost of goods sold
35,00 mjd
38,94 mjd
41,44 mjd
39,12 mjd
Cost of revenue
35,00 mjd
38,94 mjd
41,44 mjd
39,12 mjd
Research and development expenses
31,00 m
31,05 m
24,25 m
35,77 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,07 mjd
2,21 mjd
2,07 mjd
2,24 mjd
Operating expense
2,18 mjd
2,54 mjd
2,37 mjd
2,45 mjd
Total operating expenses
37,17 mjd
41,49 mjd
43,81 mjd
41,57 mjd
Operating income
1,05 mjd
577,21 m
971,28 m
922,06 m
Other non operating income
-10,19 m
-23,03 m
-15,38 m
-57,14 m
EBT including unusual items
706,81 m
590,98 m
762,47 m
810,81 m
EBT excluding unusual items
868,16 m
402,66 m
702,61 m
619,67 m
Income tax expense
148,37 m
258,61 m
167,28 m
213,41 m
Effective tax rate
20,99%
43,76%
21,94%
26,32%
Other operating expenses
7,64 m
209,56 m
45,26 m
169,00 m
Net income
529,89 m
279,41 m
733,16 m
467,41 m
Net profit margin
1,39%
0,66%
1,64%
1,10%
Earnings per share
0,10
0,05
0,11
0,08
Interest and investment income
65,37 m
122,28 m
65,73 m
31,49 m
Interest expense
-245,91 m
-262,58 m
-319,03 m
-279,26 m
Net interest expenses
-180,54 m
-140,30 m
-253,30 m
-247,77 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,22 mjd
728,70 m
1,12 mjd
1,11 mjd
Gain or loss from assets sale
-238,51 m
244,27 m
-
20,61 m
AI content may include mistakes. Learn more
Google-programme